{"id":3953,"date":"2025-06-20T18:39:58","date_gmt":"2025-06-20T15:39:58","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3953"},"modified":"2025-06-20T18:43:44","modified_gmt":"2025-06-20T15:43:44","slug":"capricor-therapeutics-announces-positive-4-year-data-of-deramiocel-cap-1002-in-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/capricor-therapeutics-announces-positive-4-year-data-of-deramiocel-cap-1002-in-duchenne-muscular-dystrophy\/","title":{"rendered":"Capricor Therapeutics, Duchenne Musk\u00fcler Distrofi'de Deramiocel'in (CAP-1002) 4 Y\u0131ll\u0131k Olumlu Verilerini Duyurdu"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Nadir hastal\u0131klar i\u00e7in d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc h\u00fccre ve ekzosom bazl\u0131 tedaviler geli\u015ftiren bir biyoteknoloji \u015firketi olan Capricor Therapeutics, bug\u00fcn Duchenne Musk\u00fcler Distrofi (DMD) i\u00e7in \u015eirketin ba\u015fl\u0131ca h\u00fccre tedavisi aday\u0131 olan Deramiocel&#039;nin devam eden HOPE-2 A\u00e7\u0131k Etiketli Uzatma (OLE) \u00e7al\u0131\u015fmas\u0131ndan d\u00f6rt y\u0131ll\u0131k olumlu g\u00fcvenlik ve etkinlik sonu\u00e7lar\u0131n\u0131 duyurdu. \u2013 Daha Fazlas\u0131n\u0131 Okuyun: <a href=\"https:\/\/dmdwarrior.com\/tr\/what-is-deramiocel\/\">Deramiocel nedir? CAP-1002 ne i\u015fe yarar?<\/a> \u2013<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">D\u00f6rt y\u0131ll\u0131k s\u00fcrekli tedaviden sonra, Deramiocel ile tedavi edilen hastalar ba\u015flang\u0131\u00e7 seviyesine k\u0131yasla -0,5 puanl\u0131k bir medyan de\u011fi\u015fim g\u00f6sterdi. Ayr\u0131ca, ba\u015flang\u0131\u00e7 LVEF &gt;45% olan hastalar\u0131n bir alt grup analizi, potansiyel olarak kardiyak fonksiyonu korumak i\u00e7in Deramiocel ile erken m\u00fcdahaleyi destekleyerek daha da b\u00fcy\u00fck bir klinik fayda g\u00f6sterdi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ek olarak, tedavi, \u00dcst Ekstremite Performans\u0131 (PUL v2.0) ile \u00f6l\u00e7\u00fcld\u00fc\u011f\u00fcnde iskelet kas\u0131 hastal\u0131\u011f\u0131n\u0131n ilerlemesini yava\u015flatmaya devam etti ve hastalar d\u00f6rd\u00fcnc\u00fc y\u0131lda (0,6 puan) birinci y\u0131la (1,8 puan) k\u0131yasla daha k\u00fc\u00e7\u00fck bir ortalama d\u00fc\u015f\u00fc\u015f ya\u015fad\u0131. <strong>Bu bulgular bir araya geldi\u011finde, Deramiocel ile uzun s\u00fcreli tedavinin DMD&#039;nin zamanla ilerlemesini hafifletmeye yard\u0131mc\u0131 olabilece\u011fini d\u00fc\u015f\u00fcnd\u00fcrmektedir.<\/strong> Deramiocel, \u00e7al\u0131\u015fma boyunca olumlu bir g\u00fcvenlik profilini s\u00fcrd\u00fcrmeye devam ediyor. \u2013 Daha Fazla Bilgi Edinin: <a href=\"https:\/\/dmdwarrior.com\/tr\/capricor-therapeutics-deramiocel-mid-cycle-review-meeting-with-fda\/\">Capricor Therapeutics, Deramiocel Konusunda FDA ile Orta D\u00f6nem \u0130nceleme Toplant\u0131s\u0131n\u0131n Tamamland\u0131\u011f\u0131n\u0131 Duyurdu<\/a> \u2013<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">PPMD Kurucu Ba\u015fkan\u0131 ve CEO&#039;su Pat Furlong, &quot;Kardiyomiyopati Duchenne&#039;de \u00f6nde gelen \u00f6l\u00fcm nedenlerinden biri olmaya devam ediyor ve hastal\u0131\u011f\u0131n bu y\u00f6n\u00fcn\u00fc ele almak sonu\u00e7lar\u0131 iyile\u015ftirmek i\u00e7in kritik \u00f6nem ta\u015f\u0131yor&quot; dedi. &quot;HOPE-2 OLE \u00e7al\u0131\u015fmas\u0131ndan elde edilen uzun vadeli veriler, \u00f6zellikle d\u00f6rt y\u0131l boyunca kardiyak stabilizasyonun g\u00f6sterilmesi a\u00e7\u0131s\u0131ndan cesaret verici. Deramiocel \u00f6nemli bir terap\u00f6tik yakla\u015f\u0131m\u0131 temsil ediyor ve hem kalp hem de kas fonksiyonunu hedefleyen tedavilerin toplulu\u011fumuza m\u00fcmk\u00fcn olan en k\u0131sa s\u00fcrede sunulmas\u0131n\u0131 sa\u011flamak i\u00e7in d\u00fczenleyici yol boyunca devam eden ilerlemeyi destekliyoruz.&quot;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Capricor Therapeutics CEO&#039;su Dr. Linda Marb\u00e1n, &quot;Bu d\u00f6rt y\u0131ll\u0131k veriler, Deramiocel&#039;nin hem kardiyak hem de iskelet kas\u0131 fonksiyonunda klinik faydas\u0131n\u0131n ve olumlu g\u00fcvenlik profilinin g\u00fcc\u00fcn\u00fc ve dayan\u0131kl\u0131l\u0131\u011f\u0131n\u0131 destekliyor&quot; dedi. &quot;BLA&#039;m\u0131z \u00f6ncelikli inceleme alt\u0131nda ve birka\u00e7 \u00f6nemli d\u00fczenleyici ad\u0131m art\u0131k tamamlanm\u0131\u015fken, potansiyel onaya do\u011fru ilerlerken odaklanma ve aciliyetle ilerliyoruz. FDA ile devam eden diyalo\u011fumuz herhangi bir gecikmeye dair kan\u0131t olmadan yolunda gidiyor. Bu program\u0131n ilerlemesinde etkili olan hastalara, ailelere ve klinisyenlere te\u015fekk\u00fcr ediyoruz.&quot;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Devam\u0131n\u0131 oku: <a href=\"https:\/\/dmdwarrior.com\/tr\/capricor-therapeutics-announces-bmd-orphan-drug-designation-and-dmd-program-regulatory-development-for-deramiocel-cap-1002\/\">Capricor Therapeutics, Deramiocel (CAP-1002) i\u00e7in BMD Yetim \u0130la\u00e7 Tan\u0131m\u0131n\u0131 ve DMD Program\u0131 D\u00fczenleyici Geli\u015fimini Duyurdu<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Capricor Therapeutics, a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company\u2019s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). &#8211; Read More: What is Deramiocel? What Does CAP-1002 Do? &#8211; After [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3954,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[90,86,87,89,85,362,301],"class_list":["post-3953","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-cap-1002","tag-capricor","tag-capricor-therapeutics","tag-cardiomyopathy","tag-deramiocel","tag-dmd-cardiomyopathy","tag-hope-2"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=3953"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/3953\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/3954"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=3953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=3953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=3953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}